

Ref. No.P-66/2026-27/43
September 29, 2026

The Relationship Manager,
Department of Corporate Relations
BSE Ltd,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

SUBJECT: SUMMARY OF PROCEEDINGS OF THE 54th ANNUAL GENERAL MEETING ('AGM') OF THE COMPANY HELD ON TUESDAY, 29TH SEPTEMBER, 2026

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform that the following businesses were transacted at the 54th Annual General Meeting ("AGM") of members of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) ("Company") held today i.e. Tuesday, 29th September, 2026 through Video Conferencing (VC) / Other Audio Visual Means (OAVM) started at 11:30 A.M. and concluded at 12:05 P.M.

Mr. Dharendra Dubey, Chairman and Managing Director, chaired the Meeting.

The requisite quorum being present, the Chairman called the Meeting to order. The Chairman addressed the members. A copy of the Investor's Presentation presented at the Annual General Meeting ('AGM') held today is attached herewith.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI Listing Regulations, the Company had provided to its members the remote e-voting facility to exercise their right to vote in respect of the resolutions proposed at the AGM, convened vide Notice dated 13th August, 2026, through e-voting platform hosted by Central Depository Services (India) Limited (CDSL) from Saturday, 26th September, 2026 (9:00 a.m. IST onwards) to Monday, 28th September, 2026 (5:00 p.m. IST). Members, who could not cast their votes through remote e-voting before the Meeting, but attended the AGM, were also provided with the facility of remote e-Voting during the AGM by CDSL.

Ordinary Business

1. Adoption of Audited Standalone Financial Statements of the Company for the financial year ended 31st March 2026, the reports of the Board of Directors and Auditors.
2. Adoption of Audited Consolidated Financial Statements of the Company for the financial year ended 31st March 2026 along with the Auditors report.
3. Declaration of dividend at the rate of Rs. 5.00/- (Rupees Five only) per share on equity shares for the year ended 31st March 2026.

Special Business

4. Appointment of a Director in place of Mrs. Mithla Dubey (DIN: 03597415) who retires by rotation and being eligible, offers herself for re-appointment.

5. Ratification of Remuneration of the Cost Auditor.

The above businesses were transacted through remote e-voting and e-voting at the Annual General Meeting as required under the Companies Act, 2013 and SEBI Listing Regulations.

Mr. Praveen Kumar Rai, Proprietor of M/s. P.K. Rai & Associates, Practicing Company Secretary, was appointed as the scrutinizer to scrutinize the remote e-voting process and e-voting process at the Annual General Meeting.

Details of voting results under Regulation 44(3) of SEBI Listing Regulations will be displayed on Company's website and shall be submitted separately to the Stock Exchanges along with Scrutinizer's Report.

Thanking you,

This is for your information and records.

Yours faithfully,
For 3B BlackBio DX Limited (Formerly, KILPEST INDIA LTD)

Navneet Kaur

Digitally signed by Navneet
Kaur
Date: 2026.09.29 14:14:10
+05'30'

Navneet Kaur
Company Secretary
ACS No.: 29130
Encls: as above



Dear Shareholders,

It gives me great pleasure to welcome you all to the 54th Annual General Meeting of 3B BlackBio Dx Limited. Today, we come together not only to review the financial outcomes of the fiscal year 2025–26 but also to reflect on the milestones and successes we have achieved as a collective.

For more than fifty years, 3B BlackBio Dx Limited has stood as a testament to resilience and innovation, continually delivering high-quality solutions to patients, clinicians, and partners. This legacy has been possible only because of the relentless commitment of our employees, the enduring loyalty of our customers, and the steadfast support of you—our esteemed shareholders. We remain grateful for your unwavering partnership throughout these decades.

The company completed the acquisition of Coris BioConcept on 29th August 2025. According to the Ind AS rules, we have consolidated the financials figures of Coris from the date of acquisition.


With this spirit, let us now turn our attention to an overview of the company's financial performance for the year ended 31st March 2026.

Consolidated* –

- Revenue from Operations - ₹ 141.91 Crores
- Profit before Tax - ₹ 76.96 Crores
- Profit after Tax - ₹ 59.92 Crores
- Earnings per share - ₹ 69.94

*Above figures include financials from Coris BioConcept.

These results reflect not only our robust operational strategies but also the strength of our brand in a competitive market. The detailed accounts for the year, along with the Directors' and Auditors' Reports, have already been circulated to you. With your permission, I would like to take them as read.





Disclaimer:

This presentation may contain some of the forward-looking statements which are completely based on the management's belief, opinion, and expectations as of today. These statements are not a guarantee of company's future performance and involve unforeseen risk and uncertainties.



India Business

In India, the company operates through three primary sales models:

- a) Tender Sales:** This accounts for approximately 5%-7% of the total sales.
- b) Reagent Rental Model:** In this model, we provide molecular diagnostic equipment to the labs / hospitals with a condition that only our assays are used, these are long-term contracts (typically signed for a duration of a minimum of 3 years) which are projected to contribute business of 20%-25% for this financial year and coming years. Currently we have over 15 contracts in place. As the model ensures 3-5 year committed business with ensured volumes, it justifies its viability.
- c) Other Supplies:** Apart from above, we sell products to hospitals and labs which comprises the remaining 65%-70% of the total sales.

Infectious disease assays contribute approximately 60% of our sales, while oncology assays contribute around 40%. This mix may vary with growth, due to competitive reasons we do not disclose the exact sales split across individual assays.

The Total Addressable Market (TAM) for Molecular Diagnostics (MDx) in India is estimated at approx. ₹500–600 Cr and we hold a 12%–15% market share, positioning ourselves among the market leaders. The MDx industry in India is projected to grow at 8%–10% CAGR over the next few years due to factors like increasing adoption of molecular diagnostics across diagnostic labs and hospitals and government projects. However, this growth is attracting increased competition which affects pricing.

Even with this, we are hoping to grow at 15%–20% for FY 2026–27, backed by our extensive product portfolio and strong market presence over the years and high-quality products well accepted by the customers.



Exports


TRUPCR® assays have gained widespread global acceptance, with a presence in over 75 countries across Europe, Middle East, Africa, APAC, LATAM and North America. Our international footprint has expanded significantly from 25 countries in 2021, supported by a growing distribution network, new product registrations, international tenders and successful customer validations. Regulatory registrations remain central to our expansion strategy and typically take 10–15 months, depending on the country and regulatory pathway. During the year, registrations were initiated in additional countries across Latin America and Asia, creating opportunities for further growth as approvals are received.

Participation in leading international exhibitions and conferences remains an important part of our global market development strategy. We will selectively participate in key events aligned with our priority markets to strengthen the TRUPCR® brand, expand our distributor and customer network, support new market entry and create sustainable business opportunities.

The export sales for FY 2025-26 were ₹ 21.41 Crs compared to ₹ 17.03 Crs in FY 2024-25. Due to confidentiality reasons, we are not giving a country wise split of the sales. At present, about 45% of exports come from Europe, ~25% from the Middle East, ~25% from APAC, and ~5% from RoW; this mix may shift with growth.

Some of our export orders were also impacted due to the geopolitical tensions in the Middle East. Our export growth would have been higher had this been more favourable.

Maintaining this momentum, we are well-positioned to further expand our international business, with a targeted growth projection of 20-25%.





UK Subsidiary – TRUPCR® Europe Limited

TRUPCR® Europe achieved sales of £1.75 Million in 2025-26 compared to sales of £1.28 Million in 2024-25 which is a growth of 36%. The major sales of ~85-90% TRUPCR Europe comes from EU and UK and ~10-15% comes from the other territories. Our UK subsidiary continues to be a strong growth driver for the group with a 57.20% CAGR over a period of last four years, with its “Made in UK” portfolio gaining steady acceptance across Europe.



The UK facility, equipped with sales, marketing, technical support, and R&D, has enabled efficient service delivery and market responsiveness. EU branding, coupled with improved logistics, has also supported successful expansion into LATAM and African markets via TPE.

The site’s ISO 13485:2016 certification by BSI, UK reinforces our commitment to quality and regulatory compliance, enhancing market access and customer confidence. Continued participation in global events such as Medica, ESHG, ACGS has helped increase brand visibility, strengthen customer relationships and support the expansion of TRUPCR® Europe across the UK, Europe and other international markets. With a CAGR of over 57% over 4 years, our UK operations are a clear testament to the success of our strategic investments. We project continued strong growth of 20–25% in the current fiscal year from TPE, positioning the UK subsidiary as a critical part of our international business expansion.



Coris BioConcept


We completed the acquisition on 29th August, and under **Ind AS** rules, we can only consolidate from the date of acquisition. So FY25-26 reflects only the post-acquisition quarters — the profitable ones.

For the Year ending ended (2025-26), if we exclude the HAT order of EUR 1.35M (EUR 510K in August & EUR 810K in December) then, the remaining sales mainly consists of three segments – AMR, Infectious and R&D.

This year we've received confirmation for a HAT order of 1.41 million euros, to be supplied in Q3, December 2026. Last year, HAT sales were 1.35 million, also supplied in December.

Coris has been granted IVDR certification for its two main AMR products — a big milestone that will help grow the market. They have also started working on US FDA registration for RESIST-5 AMR, which will take 1-2 years. This opens a big US market opportunity, with sales expected to start in 2027-28, and will also help tap into other FDA-recognizing markets.

So, to summarize, Coris will grow by 5-10% with flat EBITDA in 2026-27 and in 2027-28 they will grow by 10% with slightly positive EBITDA.





Transition to IVDR

Europe remains an important market for our diagnostics business, and therefore our transition to the new European IVDR regulatory framework continues to be a key priority for the Company.

Over the last few years, we have been systematically preparing our key TRUPCR® product portfolio for this transition. BSI Group has been appointed as our Notified Body, the required agreement is in place, and we have implemented an IVDR-aligned Quality Management System. In November 2025, we successfully completed the QMS audits conducted by BSI, which was an important milestone in the certification process.

IVDR provides a transition period for eligible legacy Class C devices until 31st December 2028, subject to fulfilment of the prescribed conditions. We have progressed in line with these requirements and have completed the applicable transition activities within the required timelines.

Our focus now is on completing the ongoing technical evaluations and obtaining IVDR certification for our key Class C TRUPCR® products well ahead of the final transition deadline. The selected products cater to approx. 90-95% revenue from the EU.

We see this not only as a regulatory requirement, but also as an important long-term investment in our European business. IVDR certification will support continued market access, strengthen the credibility of the TRUPCR® brand and provide a stronger regulatory platform for expanding our business across Europe



What Sets us Apart!

- Largest CE-IVD and Indian IVD Product Range with over 120 PCR assays developed and commercially available
- Highly experienced, strong and well retained team including Ph.Ds., MScs., MBAs in our Production, R&D, QC and Sales & Marketing.
- Only Indian molecular diagnostics company to have a subsidiary in UK and Belgium, establishing our credibility globally.
- All the sites – India, UK and Belgium, are ISO 13485 certified by BSI, UK defining the strong Quality Management System the company follows.
- We deliver orders in the shortest TAT (Turn-Around-Time) in the industry.
- Technical support in the same time zone available to the end-users both for India and EU customers giving us an added advantage over competition.
- Only molecular company globally to integrate offerings for Rapid Diagnostics (Lateral Flow) & NGS solutions and covering the entire range of molecular diagnostic solutions in its true sense



R&D

With our multidisciplinary scientific team with expertise in molecular biology, assay development, bioinformatics and diagnostic product development, R&D has always been the core strength of the company. Through our continuous R&D, we keep launching new assays. Due to competitive reasons, we can not disclose these details, however, these new assays help in maintaining our growth rate of 15-20%.

We had started with approximately 10 assays in 2016 and now have 35 assays which are giving sales of more than ₹50 lakhs although we have more than 120 products in our portfolio.

Our R&D doesn't stop at development only. We continuously improve our assay sensitivity, specificity, and workflow efficiency based on the performance data. We are doing sustained R&D expenditure with YoY growth of ~46%. In 2025-26, our R&D spend was 3.51% of revenue compared to 2.58% in 2024-25, which we plan to increase further this year.

NGS Vertical

With the TRUNGS® vertical, our main intent was to be technologically relevant so that we can offer all the molecular diagnostics solutions to our customers under one roof. Now we have a good grip of the NGS assays, however, commercialization is challenging as the field is highly competitive and labs try to make their own kits (homebrew) which is an old methodology and used in PCR as well. TRUNGS® is focused on very niche products in this segment, hence, we do not expect major high growth / revenue from NGS immediately, however, it will be gradual.



Digital PCR

Continuing our journey for R&D, our team has been working on the development of assays based on Digital PCR (dPCR) technology which enables absolute quantification of target nucleic acids. The products under this segment have been commercially launched in Q3 of FY 2025-26, although it is in very initial stage and sale is nominal.

By leveraging the capabilities of dPCR technology, our R&D team has the opportunity to develop innovative assays that address key challenges in healthcare & biotechnology. This could lead to the development of valuable diagnostic tools with significant impact on disease detection, treatment monitoring, and research advancements.

Mergers & Acquisitions

Now with a bigger fund size available, our focus is to do M&A in the USA as first preference (as it is the biggest market for Molecular), although we are also looking across other markets. Now, we can get a bigger and a profitable company with our new bigger budget. We have few consultants who have been assigned to search for companies. As M&A process is long, it takes time to find a suitable company. We are focusing to keep this vision for the next two years and if we don't find a suitable company in this time, then we will rethink the strategy for M&A and fund utilization.

Dividend

The Board of Directors of the Company are pleased to recommend a final dividend of ₹ 5.00 i.e., per equity share of face value of ₹ 10.00 each for the FY 2025-26.



I would like to invite all Members present at the Meeting who have not yet cast their votes via remote e-voting, and who are eligible to do so, to participate in the e-voting process now. Voting will remain open for 15 minutes following the conclusion of the Meeting.

The Scrutinizer will provide a report after completing the scrutiny of both the votes cast during the AGM and those submitted via remote e-voting.

As we conclude, I extend my heartfelt gratitude to all our valued customers, both domestic and international, for their unwavering support. A special thanks goes to our supply and trade partners for ensuring the timely availability of our products. We also appreciate the continuous support from the Government of India, the Ministry of Health, and the Government of Madhya Pradesh for their collaboration with our initiatives.

Lastly, I would like to thank all our stakeholders. Your support is vital in helping us build a self-sufficient company and in achieving the vision of 'AatmaNirbhar Bharat' set forth by our Hon'ble Prime Minister.

JAI HIND



Now, we request the 2 registered speakers to ask 3 questions each.